<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755404</url>
  </required_header>
  <id_info>
    <org_study_id>IP-003-05</org_study_id>
    <nct_id>NCT00755404</nct_id>
  </id_info>
  <brief_title>Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)</brief_title>
  <official_title>Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-Carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iperboreal Pharma Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iperboreal Pharma Srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is initiated in order to assess the impact of a PD solution containing
      L-carnitine on insulin sensitivity evaluated by measuring insulin requirement.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by measuring insulin requirement</measure>
    <time_frame>time 0, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of L-Carnitine containing PD solution on plasma lipids and lipoprotein profile</measure>
    <time_frame>4 weeks, time 0, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements)</measure>
    <time_frame>2 weeks, time 0, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD Solution</intervention_name>
    <description>Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD solution containing L-carnitine</intervention_name>
    <description>Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Have a diagnosis of ESRD and have been on Continuous Ambulatory Peritoneal Dialysis
             (CAPD) for at least 3 months

          3. Have Type 2 Diabetes, diagnosed according to American Diabetes Association (fasting
             glucose ≥126 mg/dl and 2 h glucose at OGTT ≥200 mg/dl), and treated with multiple
             daily insulin injection or with HbA1c &gt; 8.5% (No oral antidiabetic)

          4. Be in a stable clinical condition during the four weeks immediately prior to Screening
             Period as demonstrated by medical history, physical examination and laboratory testing

          5. Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with
             Investigators)

          6. Have not experienced peritonitis episodes in the last 3 months

          7. Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month

          8. Be treated with 3 diurnal exchange bag solutions (solution bags with 1.5% or 2.5%
             glucose) and one nocturnal exchange bag solution (Extraneal)

          9. Have Kt/V urea measurement &gt; 1.7 per week in a previous test performed within 3 months
             that should be confirmed at Baseline Visit

         10. Have a minimum weekly creatinine clearance of 45 litres in a previous test performed
             within 6 months that should be confirmed at Baseline Visit

         11. Have a D/P Creatinine ratio at Peritoneal Equilibration Test (PET) between 0.50 and
             0.81 in a previous test performed within 6 months that should be confirmed at Baseline
             Visit

         12. Have a D/P Glucose ratio at Peritoneal Equilibration Test (PET) between 0.26 and 0.49
             in a previous test performed within 6 months that should be confirmed at Baseline
             Visit

         13. Be treated by the participating clinical Investigator for a period of at least three
             months

         14. Have understood and signed the Informed Consent Form.

        Exclusion Criteria:

          1. Have a history of drug or alcohol abuse in the six months prior to entering the
             protocol

          2. Type 2 Diabetic patients under oral antidiabetic treatment with HbA1C &lt; 8.5%

          3. Be in treatment with androgens

          4. Have clinically significant abnormal liver function test (SGOT, SGPT, and gamma-GT &gt; 2
             times the upper normal limit)

          5. Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or
             low urinary tract infections, renal parenchymal infection, pericarditis, etc)

          6. Have a history of congestive heart failure and clinically significant arrhythmia

          7. Have an history of epilepsy or any CNS disease

          8. Have malignancy within the past 5 years, including lymphoproliferative disorders

          9. Have any medical condition that, in the judgment of the Investigator, would jeopardize
             the patient's safety following exposure to study drug

         10. Have a history of L-Carnitine therapy or use in the month prior to entering the
             protocol

         11. Have used any investigational drug in the 3 months prior to entering the protocol

         12. Be in pregnancy, lactation, fertility age without protection against pregnancy by
             adequate contraceptive means
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco P Schena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arduino Arduini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Iperboreal Pharma Srl</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Godi, MD</last_name>
    <phone>+39 06 79312131</phone>
    <email>lgodi@harrison-cro.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renal, Dialysis and Transplant Unit, University of Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nephology and Dialysis Unit, &quot;Salvini&quot; Hospital</name>
      <address>
        <city>Bollate</city>
        <zip>20021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, University of &quot;G. d'Annunzio&quot;</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Bonomini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, Desio Hospital</name>
      <address>
        <city>Desio</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Renzo Scanziani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Pozzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;Maria SS dello Splendore&quot; Hospital</name>
      <address>
        <city>Giulianova</city>
        <zip>64021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giancarlo Marinangeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology and Dialysis, Ospedale Policlinico Maggiore</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;G. Bernabeo&quot; Hospital</name>
      <address>
        <city>Ortona</city>
        <zip>66026</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Stingone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Unit, Policlinico MultiMedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvio V Bertoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology and Dialysis, &quot;Mazzini&quot; Hospital</name>
      <address>
        <city>Teramo</city>
        <zip>64100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Goffredo Del Rosso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>L-carnitine</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Glucose homeostasis</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

